Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy

摘要: Our group previously published data showing that patients could be stratified by constructed molecular subtype with respect to locoregional recurrence (LRR)-free survival after neoadjuvant chemotherapy and breast-conserving therapy (BCT). That study predated use of trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive patients. The current was undertaken determine the impact response in a contemporary cohort. Clinicopathologic from 751 breast cancer who received (with if HER2+) BCT 2005 2012 were identified. Hormone (HR) HER2 status used construct subtypes: HR+/HER2− (n = 369), HR+/HER2+ (n = 105), HR−/HER2+ (n = 58), HR−/HER2− (n = 219). Actuarial rates LRR determined Kaplan–Meier method compared log-rank test. Multivariate analysis performed factors associated LRR. pathologic complete (pCR) as follows: 16.5 % (HR+/HER2−), 45.7 % (HR+/HER2+), 72.4 % (HR−/HER2+), 42.0 % (HR−/HER2−) (P < 0.001). Median follow-up 4.6 years. 5-year LRR-free rate all 95.4 %. Five-year 97.2 % 96.1 % 94.4 % 93.4 % (P = 0.44). For disease, 97.4 86.7 % those did not experience pCR, respectively. 98.6 % versus 89.9 % (no pCR). On multivariate analysis, subtype, clinical stage III failure pCR Patients undergoing have excellent are affected chemotherapy.